TerminatedPhase 2NCT00509249
Aflibercept in Treating Patients With Myelodysplastic Syndromes
Studying Atypical chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Mark Kirschbaum, MDCity of Hope Medical Center
- Intervention
- ziv-aflibercept(biological)
- Enrollment
- 18 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2010
Study locations (1)
- City of Hope Medical Center, Duarte, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00509249 on ClinicalTrials.govOther trials for Atypical chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07238712Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched DonorSt. Petersburg State Pavlov Medical University
- RECRUITINGPHASE1, PHASE2NCT06523556Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic LeukemiaUma Borate
- RECRUITINGPHASE1NCT05549661Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap NeoplasmsMayo Clinic